key: cord-0721928-tf9huj27
authors: Jangra, Sonia; De Vrieze, Jana; Choi, Angela; Rathnasinghe, Raveen; Laghlali, Gabriel; Uvyn, Annemiek; Van Herck, Simon; Nuhn, Lutz; Deswarte, Kim; Zhong, Zifu; Sanders, Niek N.; Lienenklaus, Stefan; David, Sunil A.; Strohmeier, Shirin; Amanat, Fatima; Krammer, Florian; Hammad, Hamida; Lambrecht, Bart N.; Coughlan, Lynda; García‐Sastre, Adolfo; De Geest, Bruno G.; Schotsaert, Michael
title: Corrigendum: Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine
date: 2021-07-19
journal: Angew Chem Int Ed Engl
DOI: 10.1002/anie.202105635
sha: fe3920c6b93c047105eebf8d96d3fb162d165f37
doc_id: 721928
cord_uid: tf9huj27

nan

All chemicals for synthesis were purchased from Sigma-Aldrich or TCI, unless noted otherwise. IMDQ was synthesized according to literature (1) . 

First, the alcoholic hydroxyl group of cholesterol was transformed to an azide through a Mitsunobu reaction in the presence of diphenylphosphoryl azide (DPPA). Cholesterol (2.0 g, 5.17 mmol) was dissolved in a round bottom flask equipped with a stirring bar containing anhydrous THF (20 mL). Triphenylphosphine (PPh3, 1.63 g, 6.21 mmol) and diisopropyl azodicarboxylate (DIAD, 1.22 mL, 6.21 mmol) was added to the round bottom flask. Upon addition of DIAD, the reaction mixture developed a yellow colour.

After 10 minutes, DPPA (1.34 mL, 6.21 mmol) was added and the mixture stirred overnight at room temperature under inert atmosphere. The reaction mixture was reduced under vacuum and further purified by column chromatography (cyclohexane), to yield a purified withe powder (yield = 60 %). The resulting product cholesteryl-N3 was analysed by 1 H-NMR and ATR-IR.

Next, a Staudinger reduction was executed to reduce the azide group to a primary amine function with PPh3. The obtained cholesteryl-N3 (400 mg, 0.97 mmol) was transferred into a round bottom flask containing a stirring bar and dissolved in anhydrous THF (2.0 mL) under inert atmosphere. A solution of PPh3 (2.55 g, 9.72 mmol) in dry THF (5.0 mL) was added. After 30 min, 2 mL water was added and the reaction mixture stirred overnight at room temperature equipped with a balloon to trap the released nitrogen gas. The reaction mixture was diluted extensively with toluene before being reduced under vacuum by 50 °C. The crude product was purified by column chromatography using a gradient (from 95:5 DCM:MeOH to 95:5 DCM:MeOH + 1% ammonium hydroxide), yielded a white powder which was characterized by 1 H-NMR, ATR-IR and MS(yield = 98 %). 

NH2-PEG-CHOL (25 mg, 7.49 µmol) was weighted into a Schlenk tube equipped with a magnetic stirring bar and dissolved in 2.5 mL dry DMSO under inert atmosphere.

Then, 0.21 mL of cyanine5 N-hydroxysuccinimide ester (stock solution of 25 mg/mL in anhydrous DMSO, 7.86 µmol) and anhydrous TEA (5.2 µL,37.42 µmol) were added to the Schlenk tube and further stirred overnight at room temperature. After dialyzed for three days against demineralized water, Cyanine5-PEG-CHOL was isolated as a fluffy blueish powder after lyophilization.

Bovine serum albumin (BSA) was biotinylated by reacting it with 5:1 excess of biotin-NHS followed by dialysis and lyophilization. Hydrated streptavidin sensors were dipped in PBS to record a baseline for 60 seconds, followed by dipping into biotinylated BSA For confocal imaging popliteal lymph nodes where frozen in OCT cryomedium (Sakura, 4583). frozen sections (8-μm) were cut by cryostat. These sections where fixed for 4 min in PFA 2% (v/v), and washed with PBS. Images were acquired on a Zeiss LSM710 confocal microscope equipped with 488-nm, 561-nm and 633-nm lasers and with a tunable two-photon laser. Confocal imaging was done using a Leica DMI6000B microscope (10x 0.70 NA objective) coupled to an AndorDSD2 confocal scanner and a Zyla5.5 CMOS camera. Image processing was done using the ImageJ software package.

Luciferase reporter mice (IFNβ +/Δβ-luc ) with a Balb/c background, aged 7-9 weeks, were housed in individual ventilated cages and given ad libitum access to food and water. at 4°C with following primary labeled antibodies: CD3, CD20, CD11c, MHCII, CD86, CD40. Live dead ratio's where determined by staining with fixable dead/live-staining and 123count ebeads were added to determine cellularity prior to acquiring them on 123count ebeads were added to determine cellularity prior to Analysis by a BD FACS Quanto flow cytometer. Data were processed using the FlowJo software package. Hemagglutination inhibition was performed as previously described (2) . Briefly, four volumes of receptor destroying enzyme (RDE, Vibrio cholera filtrate, Sigma Aldrich, San Diego, CA, USA) were added to each volume of mouse serum. After overnight incubation at 37 °C, sera were heat-inactivated at 56 °C for 30 min in sodium citrate buffer. Four hemagglutination units of IVR-180 H1N1 virus were mixed with twofold dilutions of treated sera in a final volume of 50 μL. Mixtures of virus and diluted serum were allowed to bind for 1h at room temperature before 50 μL of 0.5% chicken red blood cell suspension was added. HI titers were read after 1h incubation on ice.

Trimeric recombinant SARS-CoV-2 spike protein was produced as previously described: only the ectodomain of the spike protein (GenBank: MN908947.3) was cloned into a mammalian expression plasmid and the cleavage site was removed and stabilizing prolines were added at position 986 and 987 (3) (4) (5) . A hexa-histidine tag as well as a T4 foldon trimerization domain was present in the plasmid for ease of purification. The spike protein was expressed in 293F cells, using the ExpiFectamine 293 Transfection Kit (Thermo Fisher). Supernatant was collected on day 3 post transfection and Ni-NTA agarose (Qiagen) was used to purify the protein. This protocol has been described in much greater detail earlier (5) . Vaccine (6 μg/mouse) was mixed with adjuvant as described below and injected once via the intramuscular route with a BD 300 μL insulin syringe in the hamstring muscles of both hind legs (50 μL/leg).

Anti-SARS-CoV-2 spike protein ELISA was performed to estimate spike-specific antibody responses upon vaccination. Briefly, maxisorp Nunc 96-well microtiter plates were coated with 50 µl per well of recombinant spike protein, diluted to a concentration of 2 µg/ml in carbonate/bicarbonate buffer and incubated overnight at 4°C. Three-fold serially diluted serum samples, starting from 1:100, were added to the antigen-coated plates followed by overnight incubation at 4°C. The plates were then washed in 1X PBS + 0.01% Tween20 and again incubated with appropriate horse-radish peroxidase (HRP)-conjugated secondary antibodies targeting total IgG, IgG1 or IgG2a antibodies (GE Healthcare). The plates were washed and developed with 50 µl of TMB substrate per well until blue color appeared. The reaction was terminated with 50 µl 1M H2SO4 and the absorbance was measured at 450 nm with 650 nm as a reference.

To measure the neutralizing potential of SARS-CoV-2 vaccine-induced sera, an in vitro microneutralization assay was performed similar to the protocol described in (6) .

Briefly, the Spike ± adjuvant-vaccinated mice sera were inactivated at 56°C for 30 min. 

QIV vaccinated mice were infected 24 days post vaccination with 100 lethal dose 50 (18,000 PFU) of egg-grown influenza IVR-180 H1N1 virus, a vaccine strain that contains the surface antigens of influenza A/Singapore/gp1908/2015 (H1N1) virus.

Morbidity and mortality were monitored for eight days. A group of age-matched naïve animals was added to the experiment to confirm the dose of virus was lethal to unvaccinated animals.

In order to make SARS-CoV-2 Spike-vaccinated BALB/c mice susceptible to challenge with wild type SARS-CoV-2 virus, airway expression of human ACE-2, the receptor for SARS-CoV-2, was obtained by intranasal transduction of mice with 2.5x10 8 PFU of adenovirus expressing h-ACE-2 (Ad5-hACE2), 4.5-weeks post-vaccination as described in (7). Five days after transduction with Ad5-hACE2, mice were challenged with 5x10 4 PFU of SARS-CoV2 isolate USA-WA1/2020 (BEI resources; NR-52281) per mice. Body weights were recorded to assess the morbidity during the days post challenge.

Plaque assays were performed to quantify and compare the lung viral titers in vaccinated versus unvaccinated mice. As described previously (2), whole lungs were harvested from the mice and homogenized in 1 ml 1XPBS. After brief centrifugation, the tissue debris was discarded and the supernatant was 10-fold serially diluted starting from 1:10 dilution. For IVR-180, MDCK cells were incubated with the lung homogenate dilutions for 1 hour at 37°C, 5% CO2 and then overlaid with a mixture of 2% oxoid agar and 2X minimal essential medium (MEM) supplemented with 1% diethyl-aminoethyl (DEAE)-dextran and 1 μg/ml tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin. After 48 hours of incubation at 37°C, 5% CO2, the plates were fixed in 4% formaldehyde and immune-stained with IVR-180-postchallenge polyclonal serum. Similarly, For SARS-CoV-2, pre-seeded Vero-E6 cells were incubated with diluted lung homogenates for 1 hour at room temperature and then overlayed with a 1ml mixture of 2% oxoid agar and 2X MEM supplemented with 2% FBS. After 72 hours of incubation at 37°C, 5% CO2, the plates were fixed in 4% formaldehyde, followed by immune-staining of infected cells with anti-mouse SARS-CoV-2 nucleoprotein and anti-mouse SARS-CoV-2 spike monoclonal antibodies. After ) . ) /

Structure−ActivityRelationships in Human Toll-Like Receptor 7-Active Imidazoquinoline Analogues

Nonsterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective

Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses. Front Immunol

A serological assay to detect SARS-CoV-2 seroconversion in humans

Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment